1. Home
  2. BBLG vs GTBP Comparison

BBLG vs GTBP Comparison

Compare BBLG & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BBLG

Bone Biologics Corp

N/A

Current Price

$2.11

Market Cap

2.4M

Sector

Health Care

ML Signal

N/A

Logo GT Biopharma Inc.

GTBP

GT Biopharma Inc.

HOLD

Current Price

$0.64

Market Cap

2.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBLG
GTBP
Founded
2004
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
2.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BBLG
GTBP
Price
$2.11
$0.64
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
37.6K
1.5M
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.30
$0.54
52 Week High
$7.74
$4.10

Technical Indicators

Market Signals
Indicator
BBLG
GTBP
Relative Strength Index (RSI) 64.95 45.16
Support Level $1.47 $0.58
Resistance Level $1.99 $0.82
Average True Range (ATR) 0.17 0.07
MACD 0.09 -0.01
Stochastic Oscillator 93.02 24.17

Price Performance

Historical Comparison
BBLG
GTBP

About BBLG Bone Biologics Corp

Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: